Skip to main content

Wave Life Sciences Ltd. (WVE) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $6.16: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.82; Below-average business quality.

Wave Life Sciences is a clinical-stage RNA medicines company developing stereopure oligonucleotides across RNAi (SpiNA), RNA editing (AIMers), antisense, and splicing modalities. Lead programs are WVE-007 (obesity, Phase 1), WVE-006 (AATD, Phase 1b/2a), and WVE-N531 (DMD, Phase... Read more

$6.16+21.7% A.UpsideScore 4.0/10#151 of 157 Biotechnology
QualityF-score3 / 9FCF yield-10.21%
Stop $5.90Target $7.47(resistance)A.R:R 0.0:1
Analyst target$22.56+266.3%16 analysts
$7.47our TP
$6.16price
$22.56mean
$43

Sell if holding. Engine safety override at $6.16: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.0/10, moderate confidence.

Passes 4/8 gates (no SEC red flags, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity and death cross (50MA < 200MA). Suitability: aggressive.

Val0.0Qual1.8Grw5.0Mom4.2Sent8.1Ins6.7Peer4.3Tech6.4Risk2.84.0OVERALL

Recent Developments — Wave Life Sciences Ltd.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
DATA_ISSUE: analyst_target_implausible (raw $22.56 vs price $6.14 — ratio 3.7×). Rejected, falling back to technical TP.
Quality below floor (1.8 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-5.8
Mkt Cap$1.2B
EV/EBITDA-3.6
Profit Mgn-255.7%
ROE-53.1%
Rev Growth316.9%
Beta-1.32
DividendNone
Rating analysts20

Quality Signals

Piotroski F3/9

Options Flow

P/C2.82bearish
IV83%elevated
Max Pain$1-83.8% vs spot

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

3 floor-breakers

Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static

Ps
0.0
Expensive valuation
Low model confidence on this dimension (20%).

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Fcf Quality
0.0
Piotroski F
3.3
Moat
4.2
Current Ratio
5.0
Cash-burning: FCF -175% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility
0.0
Put Call
0.0
Implied Vol
0.0
Debt Equity
1.9
Max Pain Risk
3.0
Short Interest
4.6
News Risk
6.0
Days To Cover
6.8
Elevated put/call: 2.82High IV: 83%Above max pain $1
GatesMomentum 4.2<4.5INSIDER 4.39%=EXTREMEDeath cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)No SEC red flagsEARNINGS PROXIMITY 71d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
31 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $6.08Resistance $7.62

Price Targets

$6
$7
A.Upside+21.3%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! DATA_ISSUE: analyst_target_implausible (raw $22.56 vs price $6.14 — ratio 3.7×). Rejected, falling back to technical TP.
! Quality below floor (1.8 < 4.0)
! Momentum score 4.2/10 — below 4.5 minimum

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-07-29 (71d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is WVE stock a buy right now?

Sell if holding. Engine safety override at $6.16: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.0/10. Specifically: High short interest: 11%; Elevated put/call ratio: 2.82; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $5.90. Score 4.0/10, moderate confidence.

What is the WVE stock price target?

Take-profit target: $7.47 (+21.7% upside). Prior stop was $5.90. Stop-loss: $5.90.

What are the risks of investing in WVE?

DATA_ISSUE: analyst_target_implausible (raw $22.56 vs price $6.14 — ratio 3.7×). Rejected, falling back to technical TP.; Quality below floor (1.8 < 4.0).

Is WVE overvalued or undervalued?

Wave Life Sciences Ltd. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 0.0/10. Verdict: Sell.

What do analysts say about WVE?

20 analysts cover WVE with a consensus score of 4.3/5. Average price target: $23.

What does Wave Life Sciences Ltd. do?Wave Life Sciences is a clinical-stage RNA medicines company developing stereopure oligonucleotides across RNAi...

Wave Life Sciences is a clinical-stage RNA medicines company developing stereopure oligonucleotides across RNAi (SpiNA), RNA editing (AIMers), antisense, and splicing modalities. Lead programs are WVE-007 (obesity, Phase 1), WVE-006 (AATD, Phase 1b/2a), and WVE-N531 (DMD, Phase 1b/2a planning NDA in 2026). No marketed products; revenue from collaborations.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · ADMA (ADMA Biologics Inc) · HRMY (Harmony Biosciences Holdings, I) · GLPG (Galapagos NV) · HALO (Halozyme Therapeutics, Inc.)